Results 21 to 30 of about 4,406,154 (211)

CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients

Journal of Hematology & Oncology, 2021
The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years. However, cytokine release syndrome (CRS) and
Mengying Ke, Liqing Kang, Ling Wang, Shu Yang, Yajun Wang, Haiyan Liu, Chunyan Gu, Hongming Huang, Ye Yang   +8 more
doaj   +1 more source

Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer

Cancer Cell International, 2021
Background Ovarian cancer is the leading cause of death from gynaecologic illnessed worldwide. Platelet-activating factor acetyl hydrolase IB2 (PAF-AH IB2) is an intracellular serine esterase that hydrolyzes platelet-activating factor, a G-protein-like ...
YingYing He, Zhicheng He, Xiaoyu Zhang, Shubai Liu   +3 more
doaj   +1 more source

Macrophage Derived Platelet Activating Factor Implicated in the Resolution Phase of Gouty Inflammation

International Journal of Inflammation, 2014
Human blood derived in vitro differentiated monocytes or macrophages are a population of cells which have been investigated over the years to determine the role these cells play in the resolution phase of gout.
Darshna Yagnik
doaj   +1 more source

Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus

Journal of Lipid Research, 2003
Platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A2 associated with lipoproteins that hydrolyzes platelet-activating factor (PAF) and oxidized phospholipids. We have developed an ELISA for PAF-AH that is more sensitive than previous
Takeshi Kujiraoka, Tadao Iwasaki, Mitsuaki Ishihara, Mayumi Ito, Makoto Nagano, Akito Kawaguchi, Sadao Takahashi, Jun Ishi, Masahiro Tsuji, Tohru Egashira, Irina P. Stepanova, Norman E. Miller, Hiroaki Hattori   +12 more
doaj   +1 more source

Structural identification of oxidized acyl-phosphatidylcholines that induce platelet activation [PDF]

, 2005
Oxidation of low-density lipoprotein (LDL) generates proinflammatory and prothrombotic mediators that may play a crucial role in cardiovascular and inflammatory diseases.
Siedler, F., Sellmayer, Alois, Gopfert, M. S., Siess, W.   +3 more
core   +1 more source

Mesenchymal Stromal Cells Modulate PAF-stimulated Equine Alveolar Macrophages [PDF]

Brazilian Archives of Biology and Technology, 2019
Platelet-activating factor (PAF) is a potent proinflammatory mediator that is produced in increased amounts in the lungs of asthmatic humans and horses.
Pedro Vicente Michelotto, Fernanda Zettel Bastos, Fernanda Cristina Mendes Barussi, Alexandra Cristina Senegaglia, Anita Nishiyama   +4 more
doaj   +1 more source

Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer

Mediators of Inflammation, 2004
This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients.
Yves Denizot, Véronique Truffinet, Stéphane Bouvier, Alain Gainant, Pierre Cubertafond, Muriel Mathonnet   +5 more
doaj   +1 more source

Platelet-Activating Factor Acetylhydrolase (PAF-AH)

Journal of Biochemistry, 2002
Platelet-activating factor (PAF) is one of the most potent lipid messengers involved in a variety of physiological events. The acetyl group at the sn-2 position of its glycerol backbone is essential for its biological activity, and its deacetylation induces loss of activity. The deacetylation reaction is catalyzed by PAF-acetylhydrolase (PAF-AH).
Hiroyuki, Arai, Hiroyuki, Koizumi, Junken, Aoki, Keizo, Inoue   +3 more
openaire   +2 more sources

The Platelet Activating Factor-Platelet Activating Factor Acetylhydrolase Enzyme Axis in Anaphylaxis: Current Evidence and Future Perspectives. [PDF]

Int J Mol Sci
Anaphylaxis is a severe systemic hypersensitivity reaction characterized by rapid onset, unpredictable clinical course, and potentially fatal outcomes.
Vignini A, Costanzo S, Martini M, Alia S, Membrino V, Di Crescenzo T, Buti E, Bilò MB.   +7 more
europepmc   +2 more sources

No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis

Mediators of Inflammation, 2003
Background: Platelet-activating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases.Aims: In this study, we ensured the role of PAF in SLE patients without renal complications.
Yves Denizot, Eric Liozon, Laurence Guglielmi, Kim Ly, Pascale Soria, Véronique Loustaud, Elisabeth Vidal, Marie Odile Jauberteau   +7 more
doaj   +1 more source